logo
Weight loss in your 40s and 50s can help slash your chronic disease risk, researchers say

Weight loss in your 40s and 50s can help slash your chronic disease risk, researchers say

Yahoo21-06-2025
Working to lose weight in your 40s and 50s may help to reduce your risk of developing a chronic disease, a new study reveals.
Researchers based in the U.K. and Finland say they found health benefits in people who lost an average of 6.5 percent of their body weight in early middle age and maintained that weight loss throughout a period of 12 to 35 years.
Those benefits especially include a lessened risk for cardiovascular disease and diabetes as well as an overall lower risk of death from chronic disease.
'The benefits of lifestyle-based weight management are widely discussed even though studies have found it surprisingly difficult to demonstrate health benefits beyond the prevention of diabetes,' University of Helsinki professor Dr. Timo Strandberg said in a statement.
Strandberg was the lead author of the study which was published recently in the journal JAMA Network Open, the open-access journal of the American Medical Association.
To reach these conclusions, the study tracked and analyzed the health of 23,000 white Europeans who were between the ages of 30 and 50 years old using data from three studies, conducted from 1985 to 1988, from 1964 to 1973, and between 2000 and 2013.
They sorted the participants into four groups: people with persistent healthy weight, people who were overweight but became a healthy weight, people who were healthy and became overweight, and people who were overweight the entire time.
'Measurement of weight and height was conducted at a time when surgical and pharmacological weight-loss interventions were nearly nonexistent,' the authors noted. The cause of weight loss was not assessed, but given the age of the participants and lack of diagnosed disease, it was more likely intentional than caused by severe chronic conditions or frailty.'
In one study, a reduction in body mass from overweight to normal weight over six years in mid-life was tied to a lower risk of developing chronic diseases. There was also a 48 percent lower risk for chronic illness compared to those who remained overweight, which largely held even after excluding participants who developed diabetes during follow-up.
Another study showed a 57 percent risk for chronic illness. A third study, with the longest follow-up period, showed that weight loss in mid-life was associated with a 19 percent reduction in overall mortality.
'I'm certain that overall prevention of overweight and obesity starting in early life is absolutely the best thing to do,' Stranberg told The Independent. 'Our study indirectly proves this by showing that persistent healthy weight over the life-course is best.'
He said that he hopes the findings will inspire people to see that lifestyle changes can lead to a longer life.
'This is particularly important today as more people are overweight than when the collection of our research data began 35 years ago,' he said in the statement.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'Menopause made me forget my name'
'Menopause made me forget my name'

Yahoo

time32 minutes ago

  • Yahoo

'Menopause made me forget my name'

"I didn't believe it could just be menopause. I thought it must be a brain tumour or dementia." Kirsty Dixon's life changed overnight when she started experiencing intense brain fog at 49 years old. Kirsty, from York, was staring at her screen at work one day, when suddenly she could not remember what she was doing. "I just asked myself 'What is my name?', and I couldn't even remember my own name. "I felt like I was going mad, I thought it was only me." The problems continued when she tried to access support. "I thought, why aren't people listening to me? "I've got something really serious going on but I can't get anyone to listen." Kirsty was told by a doctor that what she had experienced was part of the menopause. It is estimated that one in three women in the UK is going through the menopause at any given time. Kirsty, learning and development adviser at the University of York, is working to raise awareness of the lesser-known symptoms and the huge impact they can have on people's lives. "Before menopause I've always been a very bubbly person, very social, bit mischievous," she said. "Menopause came along and just put a big thunder cloud over my head. "I lost myself. The number of times my husband said 'I want my Kirsty back' while he was cuddling me and I was in floods of tears." Kirsty spent the next four years "fighting it" as she could not believe that those were menopause symptoms. Then, during lockdown, Kirsty found herself researching menopause for her work. She stumbled across an article by someone who had experienced the same symptoms as her. "I got that lightbulb moment that what I was experiencing was perfectly normal, I needed to understand it and know what I could do to help myself," she said. "I went from having this constant cloud and feeling useless, to actually owning my journey." Now aged 58, Kirsty runs two support groups for women experiencing the menopause, including a nature walking group around York, and a pop-up cafe in Acomb. They are non-profit and everyone is welcome, regardless of age or gender. She hopes the groups will encourage more people to talk about the lesser-known symptoms. "When you're going through it, it can feel so lonely," she said. "You feel like it's only you, and you think you're going mad. "One of the most important things I say to people is get your support network around you, and that's family, friends, and groups like this." Sarah Mortimer, 54, has been coming to the group since it started in 2022. She experienced an uncommon symptom of self-diagnosed burning mouth syndrome during her menopause, which involves developing blisters in the mouth with a burning feeling. "It can be really isolating, so to find groups like this is amazing," she said. "It makes a huge difference, knowing there's other people going through the same rubbish that you're going through. "It's that strength in numbers thing, and there's strength in the power of talking about the menopause." The group is based in York, but people travel from as far as Leeds, Sheffield and Beverley to attend. Kirsty says that it highlights an ongoing issue around the need for more support for people going through the menopause. "No one else was running a menopause cafe in York, so it was obviously something that was missing." She is calling for more groups like this so that people do not have to travel so far to get the support they need. "What I will say now, is as a post-menopausal woman, I am the most confident, the strongest, most creative person. "If someone said to me you can have your life again, without your menopause experience, actually, I'd say no, because it's what's made me the person I am today. "If I can get through that, I can get through anything." Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North or tell us a story you think we should be covering here. 'Fire service is helping me through the menopause' 'I mistook cancer signs for the menopause' What's the point of the menopause? NHS menopause advice

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug

Yahoo

timean hour ago

  • Yahoo

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Yahoo

timean hour ago

  • Yahoo

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31

Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store